Sakamakon Binciken
Wani gwaji da ya ɗauki shekaru biyu ya ba manyan masu shekaru 55‑80 2 g na DHA a kullum. Wannan adadi ya haɓaka matakin DHA a ruwan da ke zagaye da kwakwalwa (CSF), amma ba ya haifar da canjin girman kwakwalwa ko na gwaje‑gwajen tunani. Binciken da aka wallafa a EBioMedicine daga Yassine da ƙungiyarsa ya yi gwaji ne a kan mutane da ke ɗauke da alamar APOE ε4 da waɗanda ba su da ita – ɗaya daga cikin manyan gwaje‑gwajen da ke tantance kimiyyar omega‑3 a fagen cutar Alzheimer.
Abin Da Masana Sukayi Gwaji
DHA (docosahexaenoic acid) shi ne mai yawa a cikin ƙwayar kwakwalwa kuma yana daga cikin muhimman sinadaran omega‑3. Mutanen da ke ɗauke da APOE ε4 suna da haɗarin cutar Alzheimer da ya fi girma, kuma yadda jikinsu ke sarrafa omega‑3 na bambanta. Saboda haka, masu ƙarancin cin abincin da ke ɗauke da omega‑3 na iya amfana da ƙarin DHA.
Gwajin Phase IIa an gudanar da shi a matsayin randomised, double‑blind, placebo‑controlled (NCT03613844) a Jami'ar Southern California daga Satumba 2018 zuwa Mayu 2024. An zaɓi mahalarta bisa ga ka’idojin da ke ƙasa:
- Shekaru 55‑80, ba su da cutar dementia.
- Sun ci ƙananan adadin DHA a abinci (kasa da 200 mg a kowace rana).
- Suna da aƙalla ɗaya daga cikin alamu masu haɗari na dementia.
An zaɓi mutane 365 daga cikin 739 da aka duba. Matsakaicin shekarun su 66.4, kashi 58% mata ne, kashi 39% Hispanic, kuma kashi 47% (mutane 173) suna da alamar APEO ε4. An raba su zuwa ƙungiyoyin da ke son yin lumbar puncture (LP) don tattara cerebrospinal fluid (CSF) ko waɗanda ba su so. A kowane rukunin, an ba su zaɓi 2 g/kullum DHA ko placebo a kusan daidaitaccen rabo 1:1, inda aka yi la’akari da matsayin APOE ε4.
Nawa DHA Ya Kai Ƙwaƙwalwa?
Manufar farko ita ce tantance canjin CSF DHA‑to‑arachidonic acid (AA) ratio a cikin watanni 6. CSF taguwar da ke bayyana yanayin cikin kwakwalwa, don haka wannan alama tana nuna ko DHA ya wuce blood‑brain barrier kuma ya kai ga matakin da za a iya auna shi.
- Rukuni na DHA: an sami ƙaruwa da 0.17 (95 % CI 0.15‑0.18).
- Rukuni na placebo: an sami raguwa da –0.02 (95 % CI –0.04 to –0.0004).
- Bambanci: 0.19 (95 % CI 0.16‑0.21), p < 0.0001.
Mawallafi sun kira wannan CNS target engagement – wato DHA ta yi aikin da aka sa ran zai faru a matakin kimiyyar halitta.
Canjin Da Ba A Sa Ran Ba: APOE4 Ba Ya Tasiri Kan Shiga
Idan an yi tsammanin masu APOE ε4 za su amsa da bambanci, sakamakon ya nuna akasin haka. CSF DHA/AA ya ƙaru ba tare da la’akari da ko mutum na da alamar APOE ε4 ba (interaction p = 0.71). Dukkanin ƙungiyoyi sun ga haɓakar, don haka a wannan gwaji alamar ba ta hana DHA shiga kwakwalwa ba.
Abin Da Ya Canza Da Abin Da Bai Canza Ba
- Abin da aka canza: matakin CSF DHA/AA a cikin watanni 6.
- Abin da bai canza ba: girman kwakwalwa da ƙwarewar tunani har zuwa watanni 24. Babu bambanci a gwaje‑gwajen karshe da na farko.
Mawallafi sun kammala da cewa, duk da an samu biochemical target engagement, ba a samu tasiri a kan tunani ko girman kwakwalwa ba. Sun ba da shawarar a nan gaba a mai da hankali kan metabolism na DHA a kwakwalwa maimakon ƙara girman adadin da ake ba da shi.
Muhimman Lura
- Rashin halarta ya kai 38 %, mafi yawa saboda cutar COVID‑19, wanda ya rage yawan bayanan da aka samu a watanni 24.
- Gwajin Phase IIa ne. Manufarsa ta farko ita ce tantance target engagement; gwaje‑gwajen ƙwarewa da hotunan MRI kuwa su ne a matakai na gaba.
- Mahalarta ba su da dementia kuma suna da ƙarancin DHA a abinci. Sakamakon ba ya magana ga waɗanda suka riga sun samu dementia ko masu cin ƙifi da yawa.
- Lafiya ta kasance lafiya. Babu bambanci a yawan illa tsakanin rukuni‑rukuni, kuma ba a samu alaƙa tsakanin maganin da wani mummunan abu ba.
Abubuwan Da Za a Iya Amfani Da Su
Matsakaicin da aka yi amfani da shi: 2 g/kullum na DHA, a kwatanta da placebo. Wannan ne kawai adadin da aka gwada, don haka ba za a iya cewa ƙananan ko manyan adadi za su yi daban ba.
Lokaci: An ba da DHA har tsawon watanni 6 don auna CSF, sannan an bi mahalarta har zuwa watanni 24 don gwaje‑gwajen ƙwarewa da hotunan MRI.
Wanene ya cancanci a yi amfani da sakamakon: manya masu shekaru 55‑80, ba su da dementia, suna da ƙarancin DHA a abinci (kasa da 200 mg a rana), kuma suna da aƙalla ɗaya daga cikin alamu masu haɗari – ko da suna da alamar APOE ε4 ko ba su da ita.
Masu fatan DHA mai yawa zai kare tunani ko girman kwakwalwa – wannan gwaji bai nuna wannan a cikin shekaru 2 ba.
Masu cin isasshen DHA a halin yanzu – gwajin ya karɓi mutane masu ƙarancin cin DHA ne kawai, don haka ba ya ba da hujja ga su.
Masu da dementia – ba a bincika su ba, don haka ba a san ko DHA zai taimaka musu ba.
Mutanen da ke shan maganin ƙara jini ko wasu cututtuka – su nemi shawarar likita kafin su ɗauki manyan adadi na omega‑3. Takardar ba ta tattauna wannan yanayin ba.
Takaitaccen Bayani
Adadin 2 g na DHA a kullum yana iya shiga kwakwalwa, har ma ga masu APOE ε4. Amma a wannan gwaji ba a samu tasiri a kan girman kwakwalwa ko ƙwarewar tunani ba a tsawon shekaru 2. Tambayar da ke gabanmu ita ce menene kwakwalwa ke yi da DHA da ta kai ga ita.
Source: Yassine et al., “CNS target engagement of high‑dose DHA supplementation in older adults at risk for dementia: a randomised, double‑blind, placebo‑controlled trial,” EBioMedicine, DOI: 10.1016/j.ebiom.2026.106316. PubMed 42315445. Funded by the National Institute on Aging (R01AG057684) and the ADDF (GC‑201711‑2014197). Wannan labarin na ƙwarai ne don bayani kawai, ba magani ba.
